

1 **Identification of Novel Syncytiotrophoblast Membrane Extracellular Vesicles Derived**  
2 **Protein Biomarkers in Early-onset Preeclampsia: A Cross-Sectional Study.**

3 Toluwalase Awoyemi DPhil<sup>1\*</sup>, Shuhan Jiang MB;BS<sup>1</sup>, Bríet Bjarkadóttir DPhil<sup>1</sup>, Ms. Maryam  
4 Rahbar MSc<sup>1</sup>, Prasanna Logenthiran MB;BS<sup>1</sup>, Gavin Collett PhD<sup>1</sup>, Wei Zhang PhD<sup>1</sup>, Adam  
5 Cribbs PhD<sup>2</sup>, Ana Sofia Cerdeira PhD<sup>1</sup> & Manu Vatish DPhil<sup>1</sup>

6

7

8 1 Nuffield Department of Women's & Reproductive Health, University of Oxford, Oxford,  
9 United Kingdom

10 2 Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences,  
11 University of Oxford, Oxford, United Kingdom

12

13

14

15

16

17

18

19 **\*Corresponding author:** Dr Manu Vatish, MBBCh, BA (Hons), DPhil, MA, FMRCOG

20 [Manu.vatish@wrh.ox.ac.uk](mailto:Manu.vatish@wrh.ox.ac.uk), Phone number- +441865221009, Fax number-01865769141

21 **Address:** Nuffield Department of Women's and Reproductive Health, University of Oxford,  
22 Women's Centre, John Radcliffe Hospital, Oxford OX3 9DU, United Kingdom

23 **Abstract**

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

24 **Background:** Preeclampsia (PE), a multi-systemic hypertensive pregnancy disease that affects  
25 2-8% of pregnancies worldwide, is a leading cause of adverse maternal and fetal outcomes.  
26 Current clinical PE tests have a low positive predictive value for PE prediction and diagnosis.  
27 The placenta notably releases extracellular vesicles from the syncytiotrophoblast (STB-EV)  
28 into the maternal circulation.

29 **Objective:** To identify a difference in placenta and STB-EV proteome between PE and normal  
30 pregnancy (NP), which could lead to identifying potential biomarkers and mechanistic insights.

31 **Methods:** Using ex-vivo dual lobe perfusion, we performed mass spectrometry on placental  
32 tissue, medium/large and small STB-EVs isolated from PE (n = 6) and NP (n = 6) placentae.  
33 Bioinformatically, mass spectrometry was used to identify differentially carried proteins.  
34 Western blot was used to validate the identified biomarkers. We finished our investigation with  
35 an in-silico prediction of STB-EV mechanistic pathways.

36 **Results:** We identified a difference in the STB-EVs proteome between PE and NP. Filamin B,  
37 collagen 17A1, pappalysin-A2, and scavenger Receptor Class B Type 1) were discovered and  
38 verified to have different abundances in PE compared to NP. In silico mechanistic prediction  
39 revealed novel mechanistic processes (such as abnormal protein metabolism) that may  
40 contribute to the clinical and pathological manifestations of PE.

41 **Conclusions:** We identified potentially mechanistic pathways and identified differentially  
42 carried proteins that may be important in the pathophysiology of PE and are worth investigating  
43 because they could be used in future studies of disease mechanisms and as biomarkers.

44 **Funding:** This research was funded by the Medical Research Council (MRC Programme Grant  
45 (MR/J0033601) and the Medical & Life Sciences translational fund (BRR00142 HE01.01)

46 **Keywords:** Syncytiotrophoblast membrane extracellular vesicles (STB-EVs), Preeclampsia,  
47 Biomarkers, Proteomics, Placenta EVs, mechanisms

## 48 **Introduction**

49 Preeclampsia (PE) is a significant cause of maternal and neonatal morbidity and mortality,  
50 affecting 2-8% of all pregnancies(Lisonkova & Joseph, 2013). It is characterized by  
51 hypertension (systolic blood pressure  $\geq 140$ mmHg / diastolic pressure  $\geq 90$ mmHg), and either  
52 proteinuria (protein/creatinine ratio of  $\geq 30$  mg/mmol or more), or evidence of maternal acute  
53 kidney injury, liver dysfunction, neurological abnormalities, hemolysis, or thrombocytopenia,  
54 and/or fetal growth restriction.(“ACOG Practice Bulletin No. 202: Gestational Hypertension  
55 and Preeclampsia,” 2019; Brown et al., 2018) Predicting or early detection of PE is thus of  
56 extreme importance to reduce the chance of long term complications but this has been  
57 challenging due to the limitations of current predictive models and biochemical tests (which  
58 lack in positive predictive value)(Zeisler et al., 2016). The existing tests perform far better in  
59 ruling out rather than ruling in PE. They are also most effective shortly before the onset of the  
60 disease and within a specific time frame (1 or 2 weeks) rather than earlier in  
61 pregnancy(Thadhani et al., 2022).

62 The pathophysiology of PE implicates the placenta. It is known that PE can occur in  
63 trophoblastic tumors (without the presence of a fetus); that PE is more common in multiple  
64 pregnancy (with greater placental mass) and that it has occurred in ectopic pregnancies  
65 (excluding the involvement of the uterus)(Billieux et al., 2004; Hailu et al., 2017; C. W. G.  
66 Redman et al., 2022; Soto-Wright et al., 1995). Finally, delivery of the placenta (irrespective  
67 of gestational age) is currently the only cure for the condition(C. Redman, 2014).

68 The placental syncytiotrophoblast (STB) layer, the interface between the fetus and the mother  
69 which lies in direct contact with the maternal circulation. EVs, including STB-EVs, are  
70 membrane-bound and cell-derived particles that carry different cargos, including proteins,  
71 ribonucleic acid (RNA), deoxyribonucleic acid (DNA) and lipids(Raposo & Stoorvogel, 2013).  
72 EVs are based on size into medium/large STB-EVs (MVs, 201–1000nm) or small STB-EVs

73 ( $\leq 200\text{nm}$ )(Dragovic et al., 2015a). The release of syncytiotrophoblast extracellular vesicles  
74 (STB-EVs), including both size ranges, into the maternal circulation increases with gestation  
75 and is further elevated in PE (Germain et al., 2007; Goswamia et al., 2006). Variations in cargo  
76 content are evident among different subsets of syncytiotrophoblast-derived extracellular  
77 vesicles (STB-EVs), with medium/large STB-EVs (m/lSTB-EVs) showing higher levels of  
78 total RNA and total protein in comparison to small STB-EVs (sSTB-EVs)(Zabel et al., 2021).  
79 Additionally, distinct miRNA profiles have been noted to differ in abundance between these  
80 subsets. While limited studies have investigated disparities in EV subtypes, Keerthikumar et al  
81 reported that exosomes and other small extracellular vesicles (EVs) have a more pronounced  
82 impact on cell migration and proliferation than the larger EVs known as ectosomes  
83 (Keerthikumar et al., 2015) . Furthermore, Minciacchi et al demonstrated that large EVs exhibit  
84 greater efficiency in reprogramming fibroblasts and promoting the formation of endothelial  
85 cell tubes when compared to small EVs(Minciacchi et al., 2017).  
86  
87 In addition, when it comes to immune cell-derived EVs, large EVs were found to induce the  
88 secretion of Th2-associated cytokines, while both medium and small EVs (pelleted at 10,000g  
89 and 100,000g) triggered the release of Th1 cytokines(Tkach et al., 2017). These functional  
90 distinctions were also observed in STB-EVs. Specifically, our investigation unveiled that  
91 normal pregnancy (NP) medium/large-sized STB-EVs significantly enhanced the  
92 transcriptional expression of pro-inflammatory cytokines in contrast to pathological (PE)  
93 medium/large-sized STB-EVs(Awoyemi et al., 2021). However, there was no significant  
94 difference in the small STB-EV population between the two groups, although, in general, NP  
95 small STB-EVs exhibited a slight upregulation of the same cytokines(Awoyemi et al., 2021).  
96 It is reasonable to conduct further in-depth exploration into the qualitative functional properties  
97 of distinct STB-EVs, with the initial step being a comprehensive characterization of these

98 diverse subtypes. The presence of proteins, RNA species and DNA in EVs combined with their  
99 constitutional release as inter-cellular signaling moieties means they also have potential in  
100 disease prediction and diagnosis. Notably, these distinct STB-EV subtypes have also been  
101 identified in the bloodstream. Nakahara et al extensive review compiles a collection of studies  
102 that have specifically isolated various subtypes of EVs from maternal plasma(Nakahara et al.,  
103 2020). In this study, we performed proteomic analysis of placenta and STB-EVs in PE and NP  
104 to identify potential placenta-derived biomarkers. We also conducted in silico analysis on the  
105 proteomes to detect potential molecular targets, mechanisms, and processes of PE.

106

## 107 **Methods**

### 108 **Ethics approval and patient information**

109 Oxfordshire Research Ethics Committee C (07/H0606/148) approved this study. Normal  
110 pregnancy was a healthy singleton pregnancy with normal maternal blood pressure. PE was  
111 defined as new (after 20 weeks) systolic blood pressure 140 mmHg or diastolic pressure 90  
112 mmHg, proteinuria (protein/creatinine ratio of 30 mg/mmol or more). None of our patients had  
113 maternal acute kidney injury, liver dysfunction, neurological features, haemolysis,  
114 thrombocytopenia, and/or foetal growth restriction. This study included only early-onset PE  
115 patients (diagnosed before 34 weeks gestation). After informed consent, placenta was obtained  
116 from women undergoing elective caesarian section without labor were collected.

117

### 118 **Placenta sample preparation and syncytiotrophoblast membrane extracellular vesicles 119 (STB-EVs) enrichment.**

120 Placenta biopsies were obtained adjacent to the perfused lobe and immediately frozen at -80°C  
121 pending transfer to the Target Discovery Institute (Oxford) for proteomic analysis. We  
122 obtained STB-EVs via placental perfusion as previously described(Dragovic et al., 2015b). Our

123 STB-EV enrichment and categorization process has been deposited on EV Track  
124 (<http://www.EVTRACK.org>], EV-TRACK ID: EV 220157) with a score of 78% (the  
125 average score on EV track for 2021 is 52 %). Full details can be found in the supplemental  
126 data.

127

### 128 **Characterization of syncytiotrophoblast membrane extracellular vesicles (STB-EVs)**

129 Enriched STB-EVs were resuspended in filtered phosphate buffered saline (fPBS) and  
130 characterized with bicinchoninic acid (BCA) assay (for protein concentration) and nanoparticle  
131 tracking analysis (NTA) (for particle number and size profile). We also phenotyped the STB-  
132 EVs with transmission electron microscopy (for morphology), flow cytometry (BD  
133 Biosciences, LSRII), and western blot (for immunophenotyping). Flow cytometric analysis  
134 was performed using antibodies to placental alkaline phosphatase – PLAP- (to confirm  
135 syncytiotrophoblast origin), CD 41 (to identify co-isolated platelet EVs, CD235 a/b (to identify  
136 co-isolated red blood cell EVs), HLA class I and II (to identify co-isolated white blood cell  
137 EVs). Western blot was probed for placental alkaline phosphatase (PLAP [1.667 mg/ml] at  
138 1:1000 dilution in house antibody), the known EV markers CD 63 ([200ug/ml] at 1:1000  
139 dilution, Sc-59286, Santa Cruz Biotechnology), ALIX ([200ug/ml] at 1:1000 dilution, Sc-  
140 53538, Santa Cruz Biotechnology) and the known negative EV marker Cytochrome C  
141 ([200ug/ml] at 1:1000 dilution, Sc-13156, Santa Cruz Biotechnology) as recommended by the  
142 international society for extracellular vesicles (ISEV) and subsequently incubated with the  
143 corresponding secondary antibody anti-mouse, or anti-rabbit polyclonal goat  
144 immunoglobulins/HRP (at 1: 2000 dilution, Dako UK Ltd, Cambridgeshire UK). Details of  
145 nanoparticle tracking analysis and transmission electron microscopy can be found in the  
146 supplemental data.

147

148 **Sample preparation for Mass Spectrometric analysis and bioinformatic analysis of**  
149 **proteomic data from placenta tissue, medium/large, and small STB-EVs**

150 STB-EVs and placental tissue samples were processed for liquid chromatography mass  
151 spectrometry (LC-MS) (Target Discovery Institute, Oxford). Briefly, STB-EVs and placental  
152 tissue samples (10 µg total protein) were reduced with dithiothreitol (DTT) (final concentration  
153 5 mM) for 60 min at room temperature, then alkylated with iodoacetamide (final concentration  
154 20 mM) for 60 min at room temperature. After precipitation with methanol/chloroform, the  
155 protein pellet was resuspended in 6 M urea, and then the urea concentration was reduced to <  
156 1 M with milliQ H<sub>2</sub>O. Trypsin was added to achieve the final trypsin: protein ratio of 1:50,  
157 and the samples were digested overnight at 37°C. According to the manufacturer's instructions,  
158 peptides were purified on Waters C18 Sep-Pak cartridges. The purified peptides were dried  
159 down in a speed vac, resuspended in 2% acetonitrile/0.1% trifluoroacetic acid, and diluted 1:20  
160 before injection. Peptides were injected into an LC-MS system comprised of a Dionex ultimate  
161 3000 Nano LC (Liquid Chromatography) and a Thermo Q-Exactive mass spectrometer.  
162 Peptides were separated on a 50-cm-long EasySpray column (ES803; Thermo Fisher) with a  
163 75 µm inner diameter and a 60-minute gradient of 2% to 35% acetonitrile in 0.1% formic acid  
164 and 5% dimethyl sulfoxide (DMSO) at a flow rate of 250 nl/min. The Top 15 most abundant  
165 peaks were fragmented after isolation with a mass window of 1.6 and a resolution of 17,500.  
166 The normalized collision energy was 28% (higher collisional dissociation). Raw data was  
167 imported and analyzed with Progenesis QI (Waters) using standard settings and manually  
168 refined retention time alignment. MS/MS data was searched in Mascot (Matrix Science)  
169 against a human database (fused Uniprot/Trembl, 03/2018), with oxidation (Met), deamidation  
170 (Gln/Asn) and carbamidomethylation (Cys) fixed as variable modifications. Precursor mass  
171 tolerance was set to 10 parts-per-million (ppm) and fragment tolerance to 0.04 Da. Peptide

172 identifications were FDR (False Discovery Rate) adjusted at 1%, and identifications with  
173 Mascot score < 20 were discarded.

174

175 Raw label-free quantitation (LFQ) data was imported and analyzed in Perseus (Max Planck  
176 Institute of Biochemistry). Differential expression was performed by conducting a two-sample  
177 independent Student t-test. Multiple testing was corrected via permutation-based FDR (False  
178 Discovery Rate) with the default software settings. Proteins were considered differentially  
179 expressed if their false discovery rate (FDR) was less than 0.05 and their fold change was  
180 greater than or equal to 1 or less than or equal to -1. G: Profiler  
181 (<https://biit.cs.ut.ee/gprofiler/gost>) was used for functional enrichment analysis of the  
182 differentially expressed proteins (DEPs). The enriched pathways/terms from the KEGG  
183 database and Gene ontology database, gene ontology biological process (GO: BP), gene  
184 ontology molecular function (GO: MF), and gene ontology clinical component (GO: CC) were  
185 ascertained for each set of DEPs by applying hypergeometric testing. Multiple testing was  
186 corrected by Benjamin Hochberg correction, and the significance level was set to < 0.05. The  
187 mass spectrometry proteomics data have been deposited to the ProteomeXchange Consortium  
188 via the PRIDE partner repository with the dataset identifier PXD031953.132

189

## 190 **Bioinformatic analysis of proteomic data from placenta tissue, medium/large and small** 191 **STB-EVs**

192 Persus (Max Planck Institute of Biochemistry) was used for the analysis, along with the  
193 accompanying documentation and tutorials. To remove invalid data, we pre-processed the raw  
194 data by log transforming and filtering. Missing values were imputed at random from a normal  
195 distribution using the following parameters: width = 0.3 and downshift = 1.8. To ensure  
196 conformity to the normal distribution, the underlying distribution was visually inspected with



197 a histogram before and after missing data imputation. The data was then transformed further  
198 by deducting each (transformed) value from the highest occurring protein expression value.

199 Principal component analysis (PCA), heatmaps, and Pearson correlation matrices were used to  
200 further investigate the data. The data was analyzed using the correlation index and hierarchical  
201 clustering. A two-sample independent student t-test was used to assess differential expression.  
202 Multiple testing was corrected using permutation-based false discovery rate (FDR) with the  
203 following parameters, with significance set at less than 0.05.

#### 204 **Western Blotting**

205 To further characterize and immune-phenotype, we performed western blots on placental  
206 homogenates and STB-EV pellets. The relevant primary antibodies were used to probe all STB-  
207 EVs (as discussed in the main article). An equal amount of protein (20 micrograms) was mixed  
208 with 4 X Laemmli buffer ((180 mM Tris-Cl (pH 6.8), 6% SDS, 30% glycerol, 0.3% 2-  
209 mercaptoethanol, and 0.0015% bromophenol blue, BioRad)). After heating the sample mix for  
210 ten minutes at 70°C, an equal volume of the sample mix was loaded. Electrophoresis was  
211 performed at 150 V for 1.5 hours in a Novex minicell tank (Invitrogen, UK) filled with  
212 NuPAGE™ MOPS SDS running buffer under reducing (for PLAP, Cytochrome C, ALIX, SR-  
213 BI, Filamin B, PAPP-A2, Collagen 17 A1) and non-reducing (for CD 63) conditions on  
214 NuPAGE™ 4-12% Bis-Tris Gel 1.0 mm x 10 well gels (Invitrogen by Thermo Fisher  
215 Scientific) (Novex by Life Technologies). As a protein size marker, Precision plus protein™  
216 dual color standards (Bio-Rad Laboratories Ltd, Hertfordshire, UK) were used. Following  
217 protein separation, the proteins were transferred to a polyvinylidene difluoride (PVDF)  
218 membrane (Bio-Rad).

219 In a Novex semi-dry transfer apparatus, the PVDF membrane and gel were sandwiched  
220 between four filter paper sheets pre-soaked in anode one buffer solution (300 mM Tris, 10%

221 methanol pH 10.4) and two filter paper sheets pre-saturated with anode two buffer solution (25  
222 mM Tris, 20% methanol pH 10.4) at the bottom and three filter paper sheets pre-soaked in  
223 cathode buffer solution (25 mM Tris, 40 mM (Life Technologies, UK). For 45 minutes, the  
224 transfer was run at 25 V. The membranes were blocked for one hour with 5% Blotto  
225 (2BScientific) in 0.1% TBST (Tris-buffered saline (20 mM Tris, 137 mM NaCl, pH 7.6) and  
226 1% Tween-20, Sigma), then incubated overnight with the appropriate antibody.

227 Antibodies used were SR-BI (ab52629 [0.35  $\mu\text{g}/\mu\text{l}$ ] 1:1000 dilution, monoclonal Rabbit,  
228 Abcam), Filamin B (GTX387 [1.64  $\mu\text{g}/\mu\text{l}$ ] 1: 1000 dilution, monoclonal mouse, Insight  
229 Biotechnology), PAPP-A2 (ab59100 [1  $\mu\text{g}/\mu\text{l}$ ] 1: 2000 dilution polyclonal Rabbit, Abcam),  
230 Collagen 17 A1(ab28440 [1  $\mu\text{g}/\mu\text{l}$ ] 1: 2000 dilution polyclonal Rabbit, Abcam), and for  
231 characterization, placental alkaline phosphatase (PLAP [1.667  $\mu\text{g}/\mu\text{l}$ ] at 1:1000 dilution in  
232 house antibody), CD 63 ([200  $\mu\text{g}/\mu\text{l}$ ] at 1:1000 dilution, Sc-59286, Santa Cruz  
233 Biotechnology), Alix ([200 $\mu\text{g}/\mu\text{l}$ ] at 1:1000 dilution, Sc-53538, Santa Cruz Biotechnology),  
234 and Cytochrome C ([200  $\mu\text{g}/\mu\text{l}$ ] at 1:1000 dilution, Sc-13156, Santa Cruz Biotechnology) as  
235 recommended by the international society for extracellular Vesicles (ISEV).

236 After an overnight incubation and three five-minute TBST washes, the membranes were  
237 incubated for an hour at room temperature with the corresponding secondary antibody, anti-  
238 mouse (P044701-2) or anti-rabbit (P044801-2) polyclonal goat immunoglobulins/ horseradish  
239 peroxidase (HRP) (1: 2000 dilution, Dako UK Ltd, Cambridgeshire UK) and rinsed three times  
240 in TBST. The membranes were developed using a gel documentation system (G-Box, Syngene,  
241 Cambridge UK) running GeneSys (version 1.5.0.0, Syngene) and a chemiluminescence film  
242 (Amersham Hyperfilm<sup>TM</sup> ECL (enhanced chemiluminescence; GE Healthcare Limited,  
243 Buckinghamshire UK) to obtain the band intensity for each lane. The fold change (FC) between  
244 normal and preeclampsia samples was calculated by normalizing the comparative expression

245 analysis to the total protein loaded (using Amido Black stain) 17,18. The normalized  
246 densitometric values were statistically tested using a one-tailed Student t-test, with significance  
247 set at less than 0.05. Tables 1 and 2 show the reagents and antibodies used in western blot  
248 analysis, respectively. Details of western blot for STB-EV characterization and proteomic  
249 validation experiments can be seen in the supplemental material.

250 This study utilized 12 samples for initial discovery and 12 for targeted western blot validation

251

## 252 **Results**

### 253 *Patient demographics and clinical characteristics*

254 PE mothers (Table 1), as expected, had a significantly higher average systolic (178.83 mmHg,  
255  $P < 0.001$ ) and diastolic (109.17 mmHg,  $P < 0.001$ ) blood pressure compared to normal  
256 pregnant mothers average systolic (129.50 mmHg) and diastolic (67.00 mmHg). PE women  
257 are also significantly more likely to deliver prematurely (PE = 32.00 weeks gestation NP =  
258 39.17 weeks gestation,  $P < 0.001$ ) and have proteinuria (PE = 2.58 pluses on urine dipstick NP  
259 = 0 pluses on urine dipstick,  $P < 0.001$ ) compared to normal pregnancy

260 Finally, PE babies significantly weighed less than normal babies (PE = 1515.83g NP = 3912.50  
261 g,  $P < 0.001$ ). Surprisingly, we found no significant difference in body mass index, the gender  
262 of the child, and maternal age.

263

264

265

266

267

268

269 **Table 1.** General descriptive statistics of sample population

Characteristics	Sub-Classification	Normal Pregnancy	Preeclampsia	P Value
Sample size		6	6	
Maternal age years (mean (SD))		34.5 ± 5.39	36.33 ± 4.13	0.524
Systolic blood pressure mmHg (mean (SD))		129.5 ± 4.93	178.83 ± 12.56	<0.001
Diastolic blood pressure mmHg (mean (SD))		67 ± 6.2	109.17 ± 9.85	<0.001
Body mass index kg/m-2 (mean (SD))		29.92 ± 9.1	31.25 ± 11.12	0.825
Proteinuria plus(es) (mean (SD))		0	2.58 ± 1.2	<0.001
Gestational age at diagnosis in weeks (mean (SD))		NA	30.5 ± 3.50	0.001
Gestational age at delivery in weeks (mean (SD))		39.17 ± 0.98	32 ± 3.52	0.001
Birth weight grams (range)		3912.5 ± 730.4	1515.83 ± 600.57	<0.001
Intrauterine growth restriction (IUGR) = Yes (%)		0(0)	6(100)	0.004
Male new-born sex (%)		2(33.3)	2(33.3)	1.000


270

271 **Characterization of syncytiotrophoblast membrane extracellular vesicles (STB-EVs)**

272 Flow cytometry (Figure 1) was showed that many detected events ( $83-85 \pm 8.0-8.3\%$ ) were  
 273 negative for CD 235a (Red blood cells), CD41 (platelets) and HLA-I and II (white blood cells)  
 274 (Figure 1B) while  $92 \pm 0.9\%$  (Figure 1D and 1G) of detected events were PLAP<sup>+</sup> extracellular  
 275 vesicles (BODIPY FL N-(2-aminoethyl)-maleimide (bioM) and placental alkaline phosphatase  
 276 (PLAP) double-positive). Detergent treatment, which could break down EVs, with NP-40  
 277 confirmed that majority (99%) of our samples were largely vesicular since only  $0.1 \pm 0.12\%$   
 278 of BODIPY FL N-(2-aminoethyl)-maleimide and PLAP double-positive events were detected  
 279 (a reduction of 99%) (Figure 1E and 1H).

280 Transmission electron microscopy on 10K STB-EV pellets (Figure 2A and 2B) and 150K STB-  
 281 EVs (Figure 2C and 2D) in our sample preparation showed the typical cup-shaped morphology  
 282 of extracellular vesicles on transmission electron microscopy (TEM) within the appropriate  
 283 size range. Western blot confirmed they express the classic syncytiotrophoblast membrane

284 marker, placenta alkaline phosphatase (PLAP), the extracellular vesicle markers ALIX and CD  
285 63. In addition, they lacked the negative EV marker cytochrome C (Figure 3A). Nanoparticle  
286 tracking analysis (NTA) confirmed the homogeneity of the 150K STB-EV pellets (small STB-  
287 EVs) (Figure 3B) with a modal size of  $(205.8 \pm 67.7)$  nm and the heterogeneity of the 10K  
288 STB-EV pellets (medium/large STB-EVs) (Figure 3C) with a size range of  $(479.4 \pm 145.6)$   
289 nm.  
290




291

292

293 **Figure 1.** Flow analysis of medium/large STB-EVs in the 10K STB-EV pellet. Apogee beads  
294 mix were used to set the flow machine's light scatter resolution to 0.59-1.3  $\mu\text{m}$  and 0.24-1.3  
295  $\mu\text{m}$  silica beads(A). Figure B shows the application of SSC and FSC PMTVs as determined by  
296 apogee beads mix for the analysis of m/ISTB-EVs in the 10K pellet. An investigation gate was  
297 created to include only medium/large EVs negative for non-placental markers (C & F).  
298 Extracellular vesicles from the investigation gate were further analyzed for staining by bioM  
299 and expression of PLAP (D & G). Figure E and H shows that the bioM<sup>+</sup> PLAP<sup>+</sup> EVs were






300 sensitive to detergent treatment. The percent of B-Maleimide<sup>+</sup> PLAP<sup>+</sup> from the 0.59-1.3  $\mu$ m  
301 gate is consistent under both SSC conditions.



302

303

304 **Figure 2.** Results of STB-EV characterization. Figure A,B,C and D displays representative  
305 transmission electron microscopy (TEM) images with wide view (A and C), medium/large  
306 STB-EVs (B), and Small STB-EVs (D).





308 **Figure 3.** Results of STB-EV characterization. The western blot characterization of S STB-  
309 EVs and m/STB-EVs (A). 10K refers to m/STB-EVs and 150K refers to s STB-EVs. CYT C  
310 refers to cytochrome c. Figure 2A and 2B show the NTA results of m/STB-EVs (B) and sSTB-  
311 EVs (C).

312

313

314 *Differentially carried proteins (DCPs) in Placenta homogenate, Medium/Large STB-EVs*  
315 *and Small STB-EVs in Preeclampsia versus normal pregnancies.*

316 In total, using mass spectrometry, there were fifteen (15) proteins in the placenta, three hundred  
317 and four (304) in m/STB-EVs, and seventy-three (73) in sSTB-EVs were differentially  
318 expressed between preeclampsia (PE) and normal pregnancy (NP).

319 In the placenta (Table 2), *isoform HMG-R of High mobility group protein (HMGA1),*  
320 *Fibrinogen-like protein 1(FGL1), isoform 1 of Kinesin-like protein (KIF2A), Ig kappa chain C*  
321 *region (IGKC)* were the most abundant proteins based on fold change. Concomitantly, *serum*  
322 *paraoxonase/arylesterase 1 (PON1) and alpha-1B-glycoprotein (AIBG)* were the least  
323 abundant proteins.

324 For m/STB-EVs (Table 2), the most differentially abundant proteins were the *collagen alpha-*  
325 *1(XVII) chain (COL17A1), isoform 2 of Filamin-B (FLNB), tumor necrosis factor-alpha-*  
326 *induced protein 2 (Fragment) (TNFAIP2)* based on fold change. In contrast, the least  
327 differentially abundant proteins were *sodium-dependent phosphate transporter 1 (SLC20A1),*  
328 *methylthioribose-1-phosphate isomerase (Fragment) (MR11), prostatic acid phosphatase*  
329 *(Fragment) (ACPP)* based on fold change.

330 Finally, the sSTB-EVs (Table 2) had *solute carrier family 2, facilitated glucose transporter*  
331 *member (SLC2A11), v-type proton ATPase 16 KDa proteolipid subunit (ATP6V0C),*  
332 *pappalysin 2 (PAPP-A2)* as the most differentially abundant by fold change while *sodium-*

333 *dependent phosphate transporter 1 (SLC20A1)* and *isoform 2 of ADP-ribosylation factor*  
 334 *GTPase-activating protein (ARFGAP3)* were the least differentially abundant. There were 25  
 335 differentially carried proteins (DCPs) including *filamin B (FLNB)*, *ERO1-like protein alpha*  
 336 (*ERO1A*), *endoglin (EGLN)*, *pappalysin-2 (PAPP-A2)*, *siglec6 (SIGL6)* shared between  
 337 m/STB-EVS and sSTB-EVs and only one protein, *isoform 1 of kinesin-like protein (KIF2A)*  
 338 shared between the placenta and the m/l STB-EVs. Only one protein *chloride intracellular*  
 339 *channel protein 3 (CLIC3)*, was found in all three sample sub-types (Table 3)

340

341 **Table 2:** Top ten differentially expressed Proteins between normal and preeclampsia placentas  
 342 (bold font), medium/large STB-EVs (normal font), small STB-EVs(italics)

343

Protein	Symbol	LFC	Adjusted P. Value
Placenta			
<b>Isoform HMG-R of High mobility group protein HMG-I/HMG-Y</b>	<b>HMGA1</b>	<b>3.14</b>	<b>0.03</b>
<b>Fibrinogen-like protein 1</b>	<b>FGL1</b>	<b>2.49</b>	<b>0.04</b>
<b>Isoform 1 of Kinesin-like protein KIF2A</b>	<b>KIF2A</b>	<b>1.47</b>	<b>0.02</b>
<b>Chloride intracellular channel protein 3</b>	<b>CLIC3</b>	<b>1.09</b>	<b>0.05</b>
<b>Mesencephalic astrocyte-derived neurotrophic factor</b>	<b>MANF</b>	<b>1.02</b>	<b>0.03</b>
<b>Ig kappa chain V-I region AG</b>	<b>KV101</b>	<b>-1.02</b>	<b>0.05</b>
<b>Haloacid dehalogenase-like hydrolase domain-containing protein 2 (Fragment)</b>	<b>K7EJQ8</b>	<b>-1.23</b>	<b>0.05</b>
<b>Ig kappa chain C region</b>	<b>IGKC</b>	<b>-1.27</b>	<b>0.05</b>
<b>Alpha-1B-glycoprotein</b>	<b>A1BG</b>	<b>-1.34</b>	<b>0.05</b>
<b>Serum paraoxonase/arylesterase 1</b>	<b>PON1</b>	<b>-2.18</b>	<b>&lt;0.01</b>
Medium/Large STB-EVs			

Collagen alpha-1(XVII) chain	COL17A1	4.79	<0.01
Isoform 2 of Filamin B	FLNB	3.09	<0.01
Tumor necrosis factor alpha-inducible protein	TNFAIP2	3.03	<0.01
Minor histocompatibility antigen	HMHA1	1.59	0.03
Bridging integrator 2	BIN2	2.33	0.02
Sodium/potassium-transporting ATPase subunit beta-1	ATP1B	1.99	0.02
ERO-1 like protein alpha	ERO1L	1.97	<0.01
Endoglin	ENG	1.82	<0.01
Methylthioribose-1-phosphate isomerase (Fragment)	MRI1	-1.96	0.04
Sodium-dependent phosphate transporter 1	S20A1/SLC17A1	-5.24	0.04
Small STB-EVs			
<i>Solute carrier family 2, facilitated glucose transporter member 11</i>	<i>SLC2A11</i>	<i>8.91</i>	<i>0.01</i>
<i>V-type proton ATPase 16 kDa proteolipid subunit</i>	<i>VATL</i>	<i>7.25</i>	<i>0.02</i>
<i>Pappalysin-2</i>	<i>PAPP2</i>	<i>3.76</i>	<i>0.02</i>
<i>ERO1-like protein alpha</i>	<i>ERO1A</i>	<i>3.29</i>	<i>0.02</i>
<i>Isoform 2 of Creatine kinase U-type, mitochondrial</i>	<i>KCRU</i>	<i>3.20</i>	<i>0.02</i>
<i>SCARB1 protein</i>	<i>B7ZKQ9</i>	<i>2.95</i>	<i>0.05</i>
<i>Isoform 2 of Filamin-B</i>	<i>FLNB</i>	<i>2.92</i>	<i>0.02</i>
<i>Solute carrier organic anion transporter family member 2A1</i>	<i>SO2A1</i>	<i>2.86</i>	<i>0.02</i>
<i>Isoform 2 of Oligaccharyltransferase complex subunit TC</i>	<i>OSTC</i>	<i>2.82</i>	<i>0.02</i>
<i>SCY1-like protein 2</i>	<i>SCYL2</i>	<i>2.71</i>	<i>0.02</i>
<i>Sodium-dependent phosphate transporter 1</i>	<i>S20A1</i>	<i>-2.93</i>	<i>0.01</i>

344

345

346

347

348

349 **Table 3.** List of overlapping differentially carried proteins in the placenta, medium/large STB-  
 350 EVs and small STB-EVs  
 351

Sample types	Differentially expressed proteins (DEPs)
m/ISTB-EVs and Placenta	Kinesin-like protein
m/ISTB-EVs, sSTB-EVs and Placenta	Chloride intracellular channel protein 3
m/ISTB-EVs and sSTB-EVs	Filamin B
	Endoplasmic Reticulum Oxidoreductase Alpha
	X-linked retinitis pigmentosa GTPase regulator interacting protein 1
	Protein NDRG1
	Collagen alpha 1(XVII) chain
	Monocyte differentiation antigen CD14
	Trophoblast glycoprotein
	Heat shock-related 70 kDa protein 2
	Endoglin
	Hippocalcin-like protein 1
	SCARB1 protein
	Importin subunit alpha 7
	Protein BCAP
	Endothelial protein C receptor
	Caveolin
	Pappalysin-2
	Phosphatidylinositol 3-kinase regulatory subunit alpha
	Keratin, type I cytoskeletal 19
	Siglec6
	Protein disulfide-isomerase

	Amine oxidase [flavin-containing] A
	Copine-3
	Dolichyl-diphosphooligosaccharide
	Sodium-dependent phosphate transporter 1
	Annexin A4

352

353


354 **Validation of select proteins in the placenta homogenate, medium/Large STB-EVs, and**  
355 ***small STB-EVs***

356 We combined all the DCPs identified from the placenta, m/STB-EVs, and sSTB-EVs and  
357 selected proteins to validate based on fold change and our placenta specificity or enrichment  
358 as previously described above in the methods section. These were pappalysin A2 (*PAPP-A2*),  
359 *collagen 17A1 (COL17A1)*, *filamin B*, and *scavenger receptor class B type I (SR-BI/ SCARB1)*.

360 Validation was performed by western blot on all sample sub-types.

361 In the placenta (Figure 4A and 4D), *PAPP-A2* (FC =6.39, P Value = 0.0001) and *SR-BI* (FC =  
362 1.72, P Value = 0.04) were all differentially abundant in PE. *Filamin B* (FC = 2.59, P Value =  
363 0.12) was differentially abundant in PE but not significant while *COL17A1* was undetectable.

364 In medium/large STB-EVs (Figure 4B and 4E), pappalysin A2 (FC =5.09, P Value = 0.004),  
365 *collagen 17A1* (FC =71.21, P Value = 0.002), *filamin B* (FC =7.60, P Value = 0.014) and  
366 *scavenger receptor class B type I* (FC =2.28, P Value = 0.018) were all significantly  
367 differentially abundant in PE compared to normal. In sSTB-EVs (Figure 4C and 4F), only  
368 *filamin B* (FC =7.73, P Value = 0.003) and *SR-BI/SCARB1* (FC =1.60, P Value = 0.002) were  
369 significantly differentially abundant while *COL17A1*(FC =12.79, P Value = 0.07) and *PAPP-*  
370 *A2* (FC =1.48, P Value = 0.11) were differentially abundant but not significantly so.



371

372

373 Figure 4. Figure showing the results of western blot and densitometric verification of PAPP-  
 374 A2, COL17A1, FLNB and SR-BI in the placenta (A and D) m/STB-EVs (B and E) and sSTB-  
 375 EVs (C and F). Collagen 17A1 did not show up in the placenta homogenate. \* means < 0.05,  
 376 \*\* means < 0.01, \*\*\* means < 0.001, \*\*\*\* means less than 0.001 and ns means non-significant.

377

378 **Functional enrichment of differentially carried proteins (DCPs) in preeclampsia (PE)**

379 We performed a functional enrichment analysis on the list of differentially carried proteins in  
 380 placenta tissue, medium/large STB-EVs, and small STB-EVs to help better understand their  
 381 role in preeclampsia (PE). The three sample sub-types did not have overlapping gene ontology  
 382 terms or KEGG pathways. The top biological processes overrepresented in the placenta (Table  
 383 3A) were processes that involve *neurotransmitter secretion and transport*. In comparison, the  
 384 enriched biological processes in the m/STB-EVs (supplemental table 3) *involved responses to*  
 385 *hypoxia*. Finally, *posttranslational protein modification processes* were enriched among small  
 386 STB-EVs (supplemental table 3). *Neurotrophin signaling pathway, spinocerebellar ataxia,*

387 *and protein processing pathway* were among the over enriched KEGG pathways in the  
388 placenta, m/ISTB-EVs and sSTB-EVs respectively (Supplemental table 4).

389

## 390 **Discussion**

### 391 **Principal findings**

392 In our analysis, PE and NP have different placenta and STB-EV proteomes. Four STB-EV  
393 biomarkers—filamin B, collagen 17A1, pappalysin-A2, and scavenger Receptor Class B Type  
394 1—were verified for differential abundance. In silico investigation revealed molecular  
395 pathways such abnormal protein metabolism that may contribute to PE's clinical and  
396 pathological symptoms and inform future research.

### 397 **Results in the context of what is known.**

398 Our analysis found chloride intracellular channel 3 (CLIC3) to be the only protein differentially  
399 abundant among all sample types. CLIC3 is expressed in the placenta throughout  
400 pregnancy(Money et al., 2007) and is abundant in PE placentas compared to NP, a finding  
401 corroborated by our results. However, it has not previously been described in terms of STB-  
402 EVs. CLIC3 also recycles activated integrins back to the plasma membrane and facilitates cell  
403 migration and invasion(Dozynkiewicz et al., 2012) a process that has been identified as  
404 abnormal in PE(KHONG et al., 1986).

405 We found *COL17A1* to be more abundant in PE m/ISTB-EVs but not detectable in the placenta  
406 in both normal and PE. Although collagen 17 has not been described in preeclampsia, a protein  
407 of the same family, collagen 1 is deposited in higher amounts in the PE placenta and can induce  
408 preeclampsia-like symptoms by suppressing the proliferation and invasion of trophoblasts.  
409 This suppression was reversible by treating with ERK and B-catenin agonists(Feng et al.,  
410 2021). Likewise, *PAPP-A2* was significantly more abundant in the PE placenta and m/ISTB-  
411 EVs. *PAPP-A2* cleaves insulin-like growth factor binding protein (IGFBP-5 and, to a lesser

412 extent, IGFBP-3). PAPP-A2's mRNA and protein are differentially expressed in the placenta  
413 and maternal serum in PE patients(Whitehead et al., 2013).

414 Filamin B was significantly more abundant in PE m/ISTB-EVs and sSTB-EVs compared to  
415 NP. Filamin B participates in cellular structural mechanics and signal transduction by  
416 interacting with ion channels, signaling molecules, transmembrane proteins, and transcription  
417 factors(Zhou et al., 2010). It also suppresses tumor growth and metastasis(Iguchi et al., 2015).  
418 Interestingly, in contrast to our study wei et al described Filamin B as being up regulated in the  
419 placenta (Wei et al., 2019) . Wei et al used glyceraldehyde 3-phosphate dehydrogenase  
420 (GAPDH) as an internal reference while we used total protein normalization to Amido black  
421 to quantify and compare protein expression. GAPDH is an unreliable internal reference protein,  
422 particularly in preeclampsia(Lanoix et al., 2012) and this may explain these discordant  
423 findings. In addition, in our proteomics data, we found GAPDH to be among the most  
424 differentially expressed (upregulated) proteins.

425 Likewise, we identified scavenger receptor class B, type 1 (SCARB1/SR-BI) to be significantly  
426 increased in PE placenta, m/l and sSTB-EVs. SCARB1/SR-BI, is most abundant in the adrenal  
427 glands, placenta, liver, and brain(Ganesan et al., 2016; Shen et al., 2016). SR-BI facilitates the  
428 uptake of cholesteryl esters from high-density lipoproteins and lipid-soluble vitamin and  
429 transthyretin-bound thyroid hormone by placental trophoblast cells(Landers et al., 2018).

430 In terms of potential mechanisms of preeclampsia, we found no overlap in the biological  
431 processes and KEGG pathways among the three sample sub-type. In the placenta, gene  
432 ontology biological processes (GO: BP) involved in *neurotransmitter secretion and transport*  
433 were overrepresented while *platelet activation*, *MAPK* and *Rap 1 signaling* pathways were  
434 among the detected KEGG pathways. In m/ISTB-EVs, *protein modification process*, and  
435 *decreased oxygen level responses* were among the perturbed GO: BP terms. *Alzheimer's* and  
436 *prion disease* were among the identified KEGG pathways. In sSTB-EVs, *post-translational*



437 *modification processes and endoplasmic reticulum protein processing* were the principal GO:  
438 BP terms and KEGG pathways.

439 Recent research has shown that ischemic hypoxia and the release of proinflammatory cytokines  
440 in PE can cause protein misfolding and initiate endoplasmic reticulum (ER) stress due to  
441 hypoxia-reoxygenation damage to the endoplasmic reticulum(Gathiram & Moodley, 2016). PE  
442 can also cause posttranslational modifications to proteins, such as changing the isoelectric  
443 point, which results in different S-nitrosylation outcomes in placental proteins(Zhang et al.,  
444 2011). It is thought that the accumulation of these aggregates of unfolded protein response  
445 (UPR) or misfolded proteins contributes to the pathophysiology of PE(Gathiram & Moodley,  
446 2016). Other processes and KEGG pathways have been previously described in preeclampsia,  
447 while others found in our study are new and may warrant further research(Lee et al., 2020;  
448 Wan Shumei, Peng Ping, Qiao Lin, 2019).

#### 449 **Ideas and Speculation**

450 STB-EVs are liquid biomarkers with real-time information from the damaged placenta in PE  
451 due to their placenta-specificity. It would be interesting to test maternal plasma or serum  
452 samples for the four STB-EV indicators reported in our study.

453 It is unclear which comes first: misfolded proteins depositing in trophoblasts and preventing  
454 normal invasion, causing ischemia and endoplasmic reticulum stress, which leads to defects in  
455 trophoblast invasion, oxidative stress, and endothelial cell dysfunction, or the trophoblast  
456 invasion defects, oxidative stress, and endothelial cell dysfunction, or the misfolded proteins  
457 because of faulty invasion and oxidative stress. Further studies exploring these PE pathogenic  
458 processes would be intriguing.

459

460

461

462 **Strengths and limitations**

463 Our study explored the difference in the proteome between PE and NP by analyzing the  
464 placenta and its extracellular vesicles. This study is one of the few to do so using extracellular  
465 vesicles obtained by a physiologic technique, the *ex-vivo* dual lobe placenta perfusion.  
466 However, the control population used for this study was not gestationally age-matched because  
467 it is impossible to obtain the ideal control for early onset PE patients. Also, our sample size  
468 was small (n of 12).

469 **Conclusion**

470 Our study may have found novel STB-EV-bound protein indicators that are significantly more  
471 abundant in PE than normal. Since STB-EVs are present in the circulation from early  
472 pregnancy to term and are released more in PE, these STB-EV carried proteins may help with  
473 earlier diagnosis and mechanistic insights.

474 **Acknowledgments**

475 We acknowledge the support of the National Institute of Health Research Clinical Research  
476 Network for assistance in patient recruitment and Fenella Roseman and Lotoyah Carty,  
477 research midwives who kindly recruited the patients for this study. We acknowledge the  
478 patients who kindly consented to this research study.

479 **Competing interests:**

480 The authors declare no competing interests.

481

482

483

484

## 485 References

- 486 ACOG Practice Bulletin No. 202: Gestational Hypertension and Preeclampsia. (2019).  
487 *Obstetrics and Gynecology*. <https://doi.org/10.1097/AOG.0000000000003018>
- 488 Awoyemi, T., Motta-Mejia, C., Zhang, W., Kouser, L., White, K., Kandzija, N., Alhamlan, F.  
489 S., Cribbs, A. P., Tannetta, D., Mazey, E., Redman, C., Kishore, U., & Vatish, M.  
490 (2021). Syncytiotrophoblast Extracellular Vesicles From Late-Onset Preeclampsia  
491 Placentae Suppress Pro-Inflammatory Immune Response in THP-1 Macrophages.  
492 *Frontiers in Immunology*, 12. <https://doi.org/10.3389/FIMMU.2021.676056>
- 493 Billieux, M. H., Petignat, P., Fior, A., Mhawech, P., Blouin, J. L., Dahoun, S., & Vassilakos,  
494 P. (2004). Pre-eclampsia and peripartum cardiomyopathy in molar pregnancy: clinical  
495 implication for maternally imprinted genes. *Ultrasound in Obstetrics & Gynecology :  
496 The Official Journal of the International Society of Ultrasound in Obstetrics and  
497 Gynecology*, 23(4), 398–401. <https://doi.org/10.1002/UOG.1015>
- 498 Brown, M. A., Magee, L. A., Kenny, L. C., Karumanchi, S. A., McCarthy, F. P., Saito, S.,  
499 Hall, D. R., Warren, C. E., Adoyi, G., & Ishaku, S. (2018). Hypertensive disorders of  
500 pregnancy: ISSHP classification, diagnosis, and management recommendations for  
501 international practice. In *Hypertension*.  
502 <https://doi.org/10.1161/HYPERTENSIONAHA.117.10803>
- 503 Dozynkiewicz, M. A., Jamieson, N. B., MacPherson, I., Grindlay, J., vandenBerghe, P. V. E.,  
504 vonThun, A., Morton, J. P., Gourley, C., Timpson, P., Nixon, C., McKay, C. J., Carter,  
505 R., Strachan, D., Anderson, K., Sansom, O. J., Caswell, P. T., & Norman, J. C. (2012).  
506 Rab25 and CLIC3 Collaborate to Promote Integrin Recycling from Late  
507 Endosomes/Lysosomes and Drive Cancer Progression. *Developmental Cell*, 22(1), 131.  
508 <https://doi.org/10.1016/J.DEVCEL.2011.11.008>
- 509 Dragovic, R. A., Collett, G. P., Hole, P., Ferguson, D. J. P., Redman, C. W., Sargent, I. L., &  
510 Tannetta, D. S. (2015a). Isolation of syncytiotrophoblast microvesicles and exosomes  
511 and their characterisation by multicolour flow cytometry and fluorescence Nanoparticle  
512 Tracking Analysis. *Methods (San Diego, Calif.)*, 87, 64–74.  
513 <https://doi.org/10.1016/J.YMETH.2015.03.028>
- 514 Dragovic, R. A., Collett, G. P., Hole, P., Ferguson, D. J. P., Redman, C. W., Sargent, I. L., &  
515 Tannetta, D. S. (2015b). Isolation of syncytiotrophoblast microvesicles and exosomes  
516 and their characterisation by multicolour flow cytometry and fluorescence Nanoparticle  
517 Tracking Analysis. *Methods*, 87, 64–74. <https://doi.org/10.1016/j.ymeth.2015.03.028>
- 518 Feng, Y., Chen, X., Wang, H., Chen, X., Lan, Z., Li, P., Cao, Y., Liu, M., Lv, J., Chen, Y.,  
519 Wang, Y., Sheng, C., Huang, Y., Zhong, M., Wang, Z., Yue, X., & Huang, L. (2021).  
520 Collagen I Induces Preeclampsia-Like Symptoms by Suppressing Proliferation and  
521 Invasion of Trophoblasts. *Frontiers in Endocrinology*, 12.  
522 <https://doi.org/10.3389/fendo.2021.664766>
- 523 Ganesan, L. P., Mates, J. M., Cheplowitz, A. M., Avila, C. L., Zimmerer, J. M., Yao, Z., &  
524 Maiseyeu, A., Rajaram, M. V. S., Robinson, J. M., & Anderson, C. L. (2016). Scavenger  
525 receptor B1, the HDL receptor, is expressed abundantly in liver sinusoidal endothelial  
526 cells. *Scientific Reports*, 6. <https://doi.org/10.1038/srep20646>
- 527 Gathiram, P., & Moodley, J. (2016). Pre-eclampsia: its pathogenesis and pathophysiology.  
528 *Cardiovascular Journal of Africa*, 27(2), 71–78. <https://doi.org/10.5830/CVJA-2016-009>
- 530 Germain, S. J., Sacks, G. P., Sooranna, S. R., Soorana, S. R., Sargent, I. L., & Redman, C. W.  
531 (2007). Systemic inflammatory priming in normal pregnancy and preeclampsia: the role  
532 of circulating syncytiotrophoblast microparticles. *Journal of Immunology (Baltimore,  
533 Md. : 1950)*, 178(9), 5949–5956. <https://doi.org/10.4049/JIMMUNOL.178.9.5949>

- 534 Goswamia, D., Tannetta, D. S., Magee, L. A., Fuchisawa, A., Redman, C. W. G., Sargent, I.  
535 L., & von Dadelszen, P. (2006). Excess syncytiotrophoblast microparticle shedding is a  
536 feature of early-onset pre-eclampsia, but not normotensive intrauterine growth  
537 restriction. *Placenta*, 27(1), 56–61. <https://doi.org/10.1016/J.PLACENTA.2004.11.007>
- 538 Hailu, F. G., Yihunie, G. T., Essa, A. A., & Tsega, W. kindie. (2017). Advanced abdominal  
539 pregnancy, with live fetus and severe preeclampsia, case report. *BMC Pregnancy and*  
540 *Childbirth*, 17(1). <https://doi.org/10.1186/S12884-017-1437-Y>
- 541 Iguchi, Y., Ishihara, S., Uchida, Y., Tajima, K., Mizutani, T., Kawabata, K., & Haga, H.  
542 (2015). Filamin B enhances the invasiveness of cancer cells into 3D collagen matrices.  
543 *Cell Structure and Function*, 40(2). <https://doi.org/10.1247/csf.15001>
- 544 Keerthikumar, S., Gangoda, L., Liem, M., Fonseka, P., Atukorala, I., Ozcitti, C., Mechler, A.,  
545 Adda, C. G., Ang, C. S., & Mathivanan, S. (2015). Proteogenomic analysis reveals  
546 exosomes are more oncogenic than ectosomes. *Oncotarget*, 6(17), 15375–15396.  
547 <https://doi.org/10.18632/ONCOTARGET.3801>
- 548 KHONG, T. Y., de WOLF, F., ROBERTSON, W. B., & BROSENS, I. (1986). Inadequate  
549 maternal vascular response to placentation in pregnancies complicated by pre-eclampsia  
550 and by small-for-gestational age infants. *BJOG: An International Journal of Obstetrics*  
551 *& Gynaecology*, 93(10). <https://doi.org/10.1111/j.1471-0528.1986.tb07830.x>
- 552 Landers, K. A., Li, H., Mortimer, R. H., McLeod, D. S. A., d’Emden, M. C., & Richard, K.  
553 (2018). Transthyretin uptake in placental cells is regulated by the high-density  
554 lipoprotein receptor, scavenger receptor class B member 1. *Molecular and Cellular*  
555 *Endocrinology*, 474. <https://doi.org/10.1016/j.mce.2018.02.014>
- 556 Lanoix, D., St-Pierre, J., Lacasse, A. A., Viau, M., Lafond, J., & Vaillancourt, C. (2012).  
557 Stability of reference proteins in human placenta: General protein stains are the  
558 benchmark. *Placenta*, 33(3). <https://doi.org/10.1016/j.placenta.2011.12.008>
- 559 Lee, A., Chow, L., Skeith, L., Nicholas, J. A., Poon, M.-C., Poole, A. W., & Agbani, E. O.  
560 (2020). Platelet Membrane Procoagulation in Preeclampsia. *Blood*, 136(Supplement 1).  
561 <https://doi.org/10.1182/blood-2020-137213>
- 562 Lisonkova, S., & Joseph, K. S. (2013). Incidence of preeclampsia: risk factors and outcomes  
563 associated with early- versus late-onset disease. *American Journal of Obstetrics and*  
564 *Gynecology*, 209(6), 544.e1-544.e12. <https://doi.org/10.1016/J.AJOG.2013.08.019>
- 565 Minciacci, V. R., Spinelli, C., Reis-Sobreiro, M., Cavallini, L., You, S., Zandian, M., Li, X.,  
566 Mishra, R., Chiarugi, P., Adam, R. M., Posadas, E. M., Viglietto, G., Freeman, M. R.,  
567 Cocucci, E., Bhowmick, N. A., & Di Vizio, D. (2017). MYC Mediates Large  
568 Oncosome-Induced Fibroblast Reprogramming in Prostate Cancer. *Cancer Research*,  
569 77(9), 2306–2317. <https://doi.org/10.1158/0008-5472.CAN-16-2942>
- 570 Money, T. T., King, R. G., Wong, M. H., Stevenson, J. L., Kalionis, B., Erwich, J. J. H. M.,  
571 Huisman, M. A., Timmer, A., Hiden, U., Desoye, G., & Gude, N. M. (2007). Expression  
572 and Cellular Localisation of Chloride Intracellular Channel 3 in Human Placenta and  
573 Fetal Membranes. *Placenta*, 28(5–6), 429–436.  
574 <https://doi.org/10.1016/J.PLACENTA.2006.08.002>
- 575 Nakahara, A., Nair, S., Ormazabal, V., Elfeky, O., Garvey, C. E., Longo, S., & Salomon, C.  
576 (2020). Circulating Placental Extracellular Vesicles and Their Potential Roles During  
577 Pregnancy. *Ochsner Journal*, 20(4), 439–445. <https://doi.org/10.31486/toj.20.0049>
- 578 Raposo, G., & Stoorvogel, W. (2013). Extracellular vesicles: Exosomes, microvesicles, and  
579 friends. *Journal of Cell Biology*, 200(4), 373–383.  
580 <https://doi.org/10.1083/JCB.201211138>
- 581 Raudvere, U., Kolberg, L., Kuzmin, I., Arak, T., Adler, P., Peterson, H., & Vilo, J. (2019).  
582 G:Profiler: A web server for functional enrichment analysis and conversions of gene  
583 lists (2019 update). *Nucleic Acids Research*, 47(W1). <https://doi.org/10.1093/nar/gkz369>

- 584 Redman, C. (2014). Pre-eclampsia: A complex and variable disease. *Pregnancy*  
585 *Hypertension*, 4(3), 241–242. <https://doi.org/10.1016/J.PREGHY.2014.04.009>
- 586 Redman, C. W. G., Staff, A. C., & Roberts, J. M. (2022). Syncytiotrophoblast stress in  
587 preeclampsia: the convergence point for multiple pathways. *American Journal of*  
588 *Obstetrics and Gynecology*, 226(2S), S907–S927.  
589 <https://doi.org/10.1016/J.AJOG.2020.09.047>
- 590 Shen, W. J., Azhar, S., & Kraemer, F. B. (2016). ACTH regulation of adrenal SR-B1. In  
591 *Frontiers in Endocrinology* (Vol. 7, Issue MAY).  
592 <https://doi.org/10.3389/fendo.2016.00042>
- 593 Soto-Wright, V., Bernstein, M., Goldstein, D. P., & Berkowitz, R. S. (1995). The changing  
594 clinical presentation of complete molar pregnancy. *Obstetrics and Gynecology*, 86(5),  
595 775–779. [https://doi.org/10.1016/0029-7844\(95\)00268-V](https://doi.org/10.1016/0029-7844(95)00268-V)
- 596 Thadhani, R., Lemoine, E., Rana, S., Costantine, M. M., Calsavara, V. F., Boggess, K.,  
597 Wylie, B. J., Simas, T. A. M., Louis, J. M., Espinoza, J., Gaw, S. L., Murtha, A.,  
598 Wiegand, S., Gollin, Y., Singh, D., Silver, R. M., Durie, D. E., Panda, B., Norwitz, E.  
599 R., ... Kilpatrick, S. (2022). Circulating Angiogenic Factor Levels in Hypertensive  
600 Disorders of Pregnancy. *NEJM Evidence*, 1(12).  
601 <https://doi.org/10.1056/EVIDOA2200161>
- 602 Tkach, M., Kowal, J., Zucchetti, A. E., Enserink, L., Jouve, M., Lankar, D., Saitakis, M.,  
603 Martin-Jaular, L., & Théry, C. (2017). Qualitative differences in T-cell activation by  
604 dendritic cell-derived extracellular vesicle subtypes. *The EMBO Journal*, 36(20), 3012–  
605 3028. <https://doi.org/10.15252/EMBJ.201696003>
- 606 Wan Shumei, Peng Ping, Qiao Lin, G. Y. (2019). Expression of miR-144, titin-Ab and  
607 MAPK signal transduction pathway related proteins in pre-eclampsia patients.  
608 *INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE*,  
609 11(127), 11–20. [www.ijcem.com/ISSN:1940-5901/IJCEM0098123](http://www.ijcem.com/ISSN:1940-5901/IJCEM0098123)
- 610 Wei, J., Fu, Y., Mao, X., Jing, Y., Guo, J., & Ye, Y. (2019). Decreased Filamin b expression  
611 regulates trophoblastic cells invasion through ERK/MMP-9 pathway in pre-eclampsia.  
612 *Ginekologia Polska*, 90(1), 39–45. <https://doi.org/10.5603/GP.2019.0006>
- 613 Whitehead, C. L., Walker, S. P., Ye, L., Mendis, S., Kaitu'u-Lino, T. J., Lappas, M., & Tong,  
614 S. (2013). Placental specific mRNA in the maternal circulation are globally dysregulated  
615 in pregnancies complicated by fetal growth restriction. *Journal of Clinical*  
616 *Endocrinology and Metabolism*, 98(3). <https://doi.org/10.1210/jc.2012-2468>
- 617 Zabel, R. R., Bär, C., Ji, J., Schultz, R., Hammer, M., Groten, T., Schleussner, E., Morales-  
618 Prieto, D. M., Markert, U. R., & Favaro, R. R. (2021). Enrichment and characterization  
619 of extracellular vesicles from ex vivo one-sided human placenta perfusion. *American*  
620 *Journal of Reproductive Immunology (New York, N.Y. : 1989)*, 86(2).  
621 <https://doi.org/10.1111/AJI.13377>
- 622 Zeisler, H., Llorba, E., Chantraine, F., Vatish, M., Staff, A. C., Sennström, M., Olovsson, M.,  
623 Brennecke, S. P., Stepan, H., Allegranza, D., Dilba, P., Schoedl, M., Hund, M., &  
624 Verlohren, S. (2016). Predictive Value of the sFlt-1:PIGF Ratio in Women with  
625 Suspected Preeclampsia. *The New England Journal of Medicine*, 374(1), 13–22.  
626 <https://doi.org/10.1056/NEJMOA1414838>
- 627 Zhang, H. H., Wang, Y. P., & Chen, D. B. (2011). Analysis of nitroso-proteomes in  
628 normotensive and severe preeclamptic human placentas. *Biology of Reproduction*, 84(5),  
629 966–975. <https://doi.org/10.1095/BIOLREPROD.110.090688>
- 630 Zhou, A. X., Hartwig, J. H., & Akyürek, L. M. (2010). Filamins in cell signaling,  
631 transcription and organ development. In *Trends in Cell Biology* (Vol. 20, Issue 2).  
632 <https://doi.org/10.1016/j.tcb.2009.12.001>  
633

634 **Supplemental Material**

635 Supplemental Methods

636 Supplemental table S1-4

637 Supplemental figure S1

638 List of differentially abundant proteins and functional enrichment analysis:

639 <https://data.mendeley.com/datasets/j2x4h9ddcj/draft?a=8ccd383c-c6e5-495d-b66b->

640 [29c691608995](https://data.mendeley.com/datasets/j2x4h9ddcj/draft?a=8ccd383c-c6e5-495d-b66b-29c691608995)

641

642

643

644

645

646

647

648

649

650

651

652

653

654

655

656

657

658

659

660

661

662

663

664

665

666

667

668

669

670

671

672

673

674



675

676

677

678

679

680

681

682

683

684 **Supplemental data**

685

686

687

688

689


690

691

692

693 **Supplemental methods**

694



695

696 **Supplemental figure 1.** Flow chart illustrating the steps involved in characterizing m/ISTB-  
697 EVs and sSTB-EVs obtained via differential ultracentrifugation (10,000 and 150,000 g) of  
698 maternal perfusate. Nanoparticle trafficking analysis, transmission electron microscopy, flow  
699 cytometry, and western blot were used to characterize the pellets from both spins.



700 **Transmission electron microscopy**

701 The Sir William Dunn School of Pathology was contracted to perform transmission electron  
702 microscopy. STB-EV pellets were diluted with fPBS to produce STB-EV solutions with  
703 concentrations ranging from 0.1 to 0.3 g/l. For 2 minutes, ten microliter of the STB-EV pellet  
704 solution was applied to freshly glowing discharged carbon formvar 300 mesh copper grids,  
705 blotted with filter paper, stained with 2% uranyl acetate for 10 seconds, blotted, and air-dried.  
706 The grid's STB-EV pellets are negatively stained to increase the contrast between the STB-EV  
707 pellets and the background. The grids were imaged with a Gatan OneView CMOS camera on  
708 an FEI Tecnai 12 TEM at 120 kV.

709 **Nanoparticle tracking analysis.**

710 The Nanosight NS500 (instrument equipped with a 405 nm laser [Malvern UK]), sCMOS  
711 camera, and nanoparticle tracking analysis (NTA) software version 2.3, Build 0033 (Malvern  
712 UK)) system was used for the analysis. Instrument performance was tested with silica 100  
713 nm microspheres prior to sample analysis (Polysciences, Inc.). The samples were diluted in  
714 fPBS to a concentration to 1/100,000 based on the starting concentration. The samples were  
715 automatically injected into the sample chamber with a 1 ml syringe using the EV measurement  
716 script: prime, delay of 5, capture of 60, and repeat of 4. Camera images of the analyzed samples  
717 were captured at a level of 12. (Camera shutter speed; 15 ms and Camera gain; 350). NTA  
718 post-acquisition settings were optimized and maintained constant across samples. Each video  
719 recording was analyzed to determine the size and concentration profile of STB-EV.

720

721

722 **Western blotting**

723 **Supplemental table 1. Reagents used for western blot.**

Buffers	Power of hydrogen (pH)	Constituents
4X Laemmli reducing buffer	6.8	9 parts 4 X Laemmli buffer
		1 part 2-beta-mercaptoethanol
4X Laemmli non-reducing buffer		4 X Laemmli buffer
Anode buffer 1	10.4	300 mM Tris base (36.34 g/L)
		100 % methanol (20 mL/L)
		980 ml of ddH <sub>2</sub> O
Anode buffer 2	10.4	25 mM Tris base (3.0 g/L)
		100 % methanol (20 mL/L)
		980 ml of ddH <sub>2</sub> O
Cathode buffer	9.4	25 mM Tris base (3.0 g/L)
		40 nM 6-aminocaproic acid (5.2 g/L)
		100 % methanol (20 mL/L)
		980 mL of dH <sub>2</sub> o
10 X TBS	8	NaCl (87.6g)
		Tris base (12.1g)
		700 ml of ddH <sub>2</sub> O
TBST	8	10 X TBS (100 mL)
		0.1 % Tween-20 (1 mL)
		900 mL of ddH <sub>2</sub> O
5% Milk TBST		5g of Blotto in 100 mL of TBST

724

725

726

727

728

729

730

731 **Supplemental table 2.** Antibodies used for western blot.

Antibodies	Concentration	Dilution	Antigen	Specificity	Manufacturer
Anti-PLAP (NDOG 2)	1.6 µg/µl	1/1000	PLAP	STB-EV	In house antibody
Anti-CD63	200 µg/µl	1/1000	CD63	STB-EV	Santa Cruz Biotechnology
Anti-ALIX	200 µg/µl	1/1000	ALIX	S STB-EV	Cell Signalling
Anti-Cytochrome C	200 µg/µl	1/500	Cytochrome C	Placenta homogenate	Santa Cruz Biotechnology
Anti-SR-BI	0.35 µg/µl	1/1000	SR-BI	N/A	Abcam
Anti-Filamin B	1.64 µg/µl	1/1000	Filamin B	N/A	Insight Biotechnology
Anti-PAPP-A2	1 µg/µl	1/2000	PAPP-A2	N/A	Abcam
Anti-Collagen 17 A1	1 µg/µl	1/1000	Collagen 17 A1	N/A	Abcam
Polyclonal goat-anti-mouse/rabbit immunoglobulin HRP		1/2000	Mouse and Rabbit Immunoglobulins	N/A	Dako UK Ltd

732

733 **Bioinformatic analysis of proteomic data from placenta tissue, medium/large and small**

734 **STB-EVs**

735 Persus (Max Planck Institute of Biochemistry) was used for the analysis, along with the  
 736 accompanying documentation and tutorials. To remove invalid data, we pre-processed the raw  
 737 data by log transforming and filtering. Missing values were imputed at random from a normal  
 738 distribution using the following parameters: width = 0.3 and downshift = 1.8. To ensure  
 739 conformity to the normal distribution, the underlying distribution was visually inspected with  
 740 a histogram before and after missing data imputation. The data was then transformed further  
 741 by deducting each (transformed) value from the highest occurring protein expression value.

742 Principal component analysis (PCA), heatmaps, and Pearson correlation matrices were used to  
 743 further investigate the data. The data was analyzed using the correlation index and hierarchical  
 744 clustering. A two-sample independent student t-test was used to assess differential expression.  
 745 Multiple testing was corrected using permutation-based false discovery rate (FDR) with the  
 746 following parameters, with significance set at less than 0.05.

747 **Functional enrichment of differentially expressed proteins (DEPs) in preeclampsia (PE)**

748 **Supplemental table 3:** The top three functionally enriched gene ontologies are: biological

749 process (GO: BP) Placenta (bold font), medium/large STB-EVs (normal font), and small STB-

750 EVs (italics).

751

Biological Process (BP)	Adjusted P Values	No of Proteins in BP terms	No of DEP queried	No of DEP found in BP terms
<b>Negative regulation of neurotransmitter secretion</b>	<b>0.02</b>	<b>2</b>	<b>14</b>	<b>2</b>
<b>Negative regulation of synaptic vesicle exocytosis</b>	<b>0.02</b>	<b>2</b>	<b>14</b>	<b>2</b>
<b>Negative regulation of neurotransmitter transport</b>	<b>0.05</b>	<b>3</b>	<b>14</b>	<b>2</b>
Response to decreased oxygen levels	0.00	84	293	30
Cellular response to decreased oxygen levels	0.00	59	293	24
Cellular ketone metabolic process	0.00	65	293	26
<i>Peptidyl-asparagine modification</i>	<i>0.02</i>	<i>10</i>	<i>73</i>	<i>5</i>
<i>Protein N-linked glycosylation via asparagine</i>	<i>0.02</i>	<i>10</i>	<i>73</i>	<i>5</i>
<i>Protein N-linked glycosylation</i>	<i>0.02</i>	<i>16</i>	<i>73</i>	<i>6</i>

752

753

754

755

756

757

758

759

760

761

762 **Supplemental table 4:** The top three functionally enriched KEGG Pathways in the placenta,  
763 medium/large STB-EVs, and small STB-EVs (only 1 KEGG). Placenta (bold font),  
764 medium/large STB-EVs (normal font), and small STB-EVs (italics)

KEGG Pathways (KP)	Adjusted Values	P	No of Proteins in KP terms	No of DEP queried	No of DEP found in KP terms
<b>Neurotrophin signalling pathway</b>	<b>0.00</b>		<b>13</b>	<b>14</b>	<b>3</b>
<b>Long-term potentiation</b>	<b>0.01</b>		<b>6</b>	<b>14</b>	<b>2</b>
<b>Renal cell carcinoma</b>	<b>0.02</b>		<b>11</b>	<b>14</b>	<b>2</b>
Proteasome	0.00		35	293	17
Spinocerebellar ataxia	0.00		48	293	21
Alzheimer disease	0.01		94	293	29
<i>Protein processing in endoplasmic reticulum</i>	<i>0.02</i>		<i>60</i>	<i>73</i>	<i>10</i>

765  
766 **Major Resources Table**

767 **Antibodies**

Target antigen	Vendor or Source	Catalog #	Working concentration	Dilution
PLAP	In house antibody		1.6 µg/µl	1/1000
CD63	Santa Cruz Biotechnology	sc-365604	200 µg/µl	1/1000
ALIX	Cell Signalling	#2171	200 µg/µl	1/1000
Cytochrome C	Santa Cruz Biotechnology	sc-13560	200 µg/µl	1/500
SR-BI	Santa Cruz Biotechnology	ab52629	0.35 µg/µl	1/1000
Filamin B	Insight Biotechnology	GTX387	1.64 µg/µl	1/1000
PAPP-A2	Abcam	ab59100	1 µg/µl	1/1000
Collagen 17A1	Abcam	Ab28440	1 µg/µl	1/2000
Mouse Immunoglobulins	Dako UK Ltd	P044701	1 µg/µl	1/2000
Rabbit Immunoglobulins	Dako UK Ltd	P044801	1 µg/µl	1/2000

768  
769  
770  
771  
772  
773  
774  
775  
776  
777  
778  
779  
780  
781

782 **Flow cytometry resources**

Markers	Fluorochromes	Clone	CAT	Isotype	Dilution / Concentration
CD41	PE Vio770	REA386	130-105-562	REA	1 in 50 for dump channel analysis.
CD235	PE Vio770	RAE-175	130-100-258	REA	
HLA Class-I (ABC)	PE Vio770	REA230	130-101-460	REA	
HLA Class-II (DRDPDQ)	PE Vio770	RAE-332	130-104-828	REA	
REA control				REA	
CD41	Pacific blue	HIP8	303713	Mouse IgG1	1 in 100
CD235	Pacific blue	HI264	349107	Mouse IgG2a	1 in 100
HLA Class-I (ABC)	Pacific blue	W6/32	311417	Mouse IgG2a	1 in 100
PLAP	PE	Mouse mAb	N/A	IgG1	0.2mg/ml
IgG2a isotype control	Pacific blue	MOPC-173	981904	IgG2a	1 in 500
IgG1 isotype control	Pacific blue	MOPC-21	400131	IgG1	1 in 200
bioM	FITC	NA	NA	NA	0.5-1nM

783

784

785

786

787

788

789